FDA Rejects Replimune's Skin Cancer Drug for Second Time

The FDA rejected Replimune Group's experimental melanoma treatment for the second time on April 10, 2026, following an initial rejection in July 2025. The drug candidate, an engineered virus designed to stimulate the immune system against advanced skin cancer, has become a focal point in debates over changing approval standards at the agency. Vinay Prasad, appointed as the FDA's head of biologics in May 2025, previously criticized regulators as an academic oncologist for approving drugs with insufficient data. The July 2025 rejection was widely interpreted as signaling Prasad's stricter regulatory stance, making the repeated rejections significant beyond just Replimune's commercial prospects.

FDA's Second Rejection of Replimune's Melanoma Treatment

• ▪The Food and Drug Administration rejected Replimune Group's experimental treatment for advanced skin cancer on Friday, April 10, 2026
• ▪Replimune Group's treatment is an engineered virus designed to rev up the immune system against melanoma
• ▪The April 2026 rejection was the second time the FDA rejected Replimune Group's skin cancer treatment
• ▪Replimune Group's melanoma drug was initially rejected by the FDA in July 2025

Debate Over Shifting FDA Approval Standards Under New Leadership

• ▪The Replimune decision in July 2025 was viewed as a possible sign of a stricter stance Vinay Prasad might take at the FDA
• ▪Vinay Prasad criticized regulators for approving drugs with limited data as an academic oncologist
• ▪Replimune Group's skin cancer treatment has been a flashpoint in a debate over shifting standards at the FDA
• ▪Vinay Prasad was appointed the FDA's head of biologics in May 2025

Perspective of Vinay Prasad

• ▪Vinay Prasad's academic criticism of drug approvals based on limited data influenced expectations about his regulatory philosophy at the FDA
• ▪Vinay Prasad's July 2025 decision to reject Replimune Group's melanoma drug was interpreted as signaling a stricter regulatory approach at the FDA

Perspective of Replimune Group

• ▪Replimune Group's melanoma drug became central to broader debates about evolving FDA approval standards under new leadership